Edison LIU

Honorary Joint Professor


Honorary Joint Professor, Department of Biochemistry, Yong Loo Lin School of Medicine, NUS.
President and CEO, The Jackson Laboratory, USA.
Adjunct Professor, Johns Hopkins, Division of Molecular Medicine, Department of Medicine.
Adjunct Professor, Molecular and Cellular Biology at the University of Champaign-Urbana.
President, Human Genome Organisation (HUGO).
Keystone Symposia Scientific Advisory Board.


Degree and Institution Year(s)
Postdoctoral Fellow - Dept. of Microbiology, University of California at San Francisco, CA (Dr. J. Michael Bishop). 1983-1987
Hematology Fellowship, University of California San Francisco, Moffitt Hospital. 1982-1985
Oncology Fellowship, Stanford University. 1979-1982
Residency, Barnes Hospital - Washington University, St. Louis. 1978-1979
Internship, Barnes Hospital - Washington University, St. Louis. 1978-1979
Stanford University, M.D. 1973-1978
Stanford University, B.S. Chemistry, Psychology. 1969-1973

Professional Experience

Position and Institute Year(s)
President and CEO of The Jackson Laboratory, USA 2012 – present
Adjunct Professor of Molecular and Cellular Biology at the University of Champaign-Urbana present
Professor, Department of Community, Occupational and Family Medicine (COFM), National University of Singapore present
Executive Director, Genome Institute of Singapore, A*STAR 2001 – 2011
President, HUGO (Human Genome Organisation) 2007-2009
Chairman, Health Sciences Authority (HSA), Singapore 2007-2009
Keystone Symposia Scientific Advisory Board 2007-present
Visiting Scientist, RIKEN Institute, Japan 2007
Adjunct Professor of Johns Hopkins, Division of Molecular Medicine, Department of Medicine 2006 – present
Board Member, National Healthcare Group (NHG), Singapore 2006
Deputy Chairman, Health Sciences Authority (HSA), Singapore 2006
Member, NUS High School Board of Governors 2005-2008
Member, Editorial Advisory Board, Biomolecular Frontiers, National University of Singapore (NUS) 2006
Member, Search Committee for Deputy President (Research & Technology, NUS) 2005
FANTOM3 working group member 2004
University Autonomy, Governance, and Funding Steering Committee (MOE, Singapore, Member) 2004
Bioethics Advisory Committee (Member), Singapore 2003
National Health Group, Strategic Committee for Clinical Research (Singapore) 2002-2003
Biomedical Sciences Executive Committee, A*STAR (Singapore) 2002
General Motors Award, General Assembly (USA) 2002-2006
National University of Singapore: Feasibility study team for the establishment of a multicampus university. 2002
Ministerial committee to revaluate Singapore’s secondary school system (Ministry of Education) 2002
President’s Life Sciences Committee (National University of Singapore) 2001
University Promotion and Tenuring Committee (National University of Singapore) 2001
Genetically Modified Organisms Advisory Council (Singapore Government) 2001-2003
NCI-Ireland-Northern Ireland Cancer Consortium Governing Board (Member) 2000-2001
Chair, General Motors Cancer Research Awards Committee: Mott Award 1999-2000
NIH Committee to establish NIH graduate program 1999-2001
NIH Building 10 Revitalization Committee 1998-2001
NCI Breast Cancer Program Review Group 1997-1998
NIH Clinical Research Revitalization Committee 1997-2001
Co-Chair, NIH Clinical Center Advisory Council 1997-2001
Chairman, NIH Committee on Extramural/Intramural Investigations in the Clinical Center 1997
Molecular Epidemiology Coordinating Group, NCI 1997
SBRS Policy Board, NIH 1997
AACR - Clinical Cancer Research Committee 1996
NCI - Clinical Trials Working Group 1996
NCI - Cancer Genetics Working Group 1996
NCI - Developmental Diagnostics Working Group 1996
NIH Committee on the Recruitment and Career Development of Clinical Investigators 1996-1997
Protocol Review and Monitoring Committee, NCI 1996
Faculty Search Committee, Division of Molecular Genetics 1996
Executive Committee: Clinical Cancer Program 1996
Advisory Committee: Clinical Cancer Program 1996
Director, Division of Clinical Sciences, National Cancer Institute, Bthesda, MD 1996-2001
Chief, Division of Medical Genetics, School of Medicine 1995–1996
National Action Plan on Breast Cancer - Biological Resources Working Group 1995–1996
Professor, Departments of Medicine, Epidemiology, Biochemistry and Biophysics 1995–1996
Faculty Search Committee: Cell Biology Program, Lineberger Cancer Center 1994
Associate Professor, Departments of Medicine and Epidemiology and Biochemistry, University of North Carolina at Chapel Hill 1993–1995
Director, Specialized Program of Research Excellence in Breast Cancer (NIH Designated) 1992-1996
American Society for Clinical Oncology: Program Committee 1992-1994
Faculty Search Committee Program in Molecular Biology 1992
Lineberger Cancer Center, SPA personnel compensation Committee 1990-1992
Lineberger Cancer Center Seminar Committee 14th Annual Symposium 1990
Lineberger Cancer Center Seminar Committee 1989
Assistant Professor in Medicine and Oncology, School of Medicine University of North Carolina at Chapel Hill 1987–1993

Research Interest

My earlier work focused on the discovery of kinases involved in cancer biology and in molecular clinical epidemiology. During this period, I discovered and investigated a new class of receptor tyrosine kinases (AXL) involved in invasion and metastases, and determined the importance of HER2 in modulating breast cancer response to specific forms of adjuvant chemotherapy. Since 1998, my scientific research has focused on the functional genomics of human cancers investigating the dynamics of gene regulation on a genome scale that modulates cancer biology. We have explored the expression signatures in breast cancers that define biochemical and genetic perturbations. From this point, we have pursued the transcriptional regulation by estrogen receptor on a genomic scale. Collectively, my work spans cancer biology, genomics, human genetics, and molecular epidemiology.

Selected Publications

  1. Liu ET. Integrative biology--a strategy for systems biomedicine. Nat Rev Genet. 2009 Jan;10(1):64-8. PMID: 19092836 [PubMed - indexed for MEDLINE]

  2. Zhang J, Liu X, Datta A, Govindarajan K, Tam WL, Han J, George J, Wong C, Ramnarayanan K, Phua TY, Leong WY, Chan YS, Palanisamy N, Liu ET., Karuturi KM, Lim B, Miller LD. RCP is a human breast cancer-promoting gene with Ras-activating function. J Clin Invest. 2009 Aug;119(8):2171-83. doi: 10.1172/JCI37622. Epub 2009 Jul 20. PMID: 19620787 [PubMed - indexed for MEDLINE]

  3. Pan YF, Wansa KD, Liu MH, Zhao B, Hong SZ, Tan PY, Lim KS, Borque G, Liu ET., Cheung E. Regulation of estrogen receptor-mediated long-range transcription via evolutionarily conserved distal response elements. J Biol Chem. 2008 Aug 25. [Epub ahead of print] PMID: 18728018 [PubMed - as supplied by publisher]

  4. Jiang X, Tan J, Li J, Kivimäe S, Yang X, Zhuang L, Lee PL, Chan MT, Stanton LW, Liu ET., Cheyette BN, Yu Q. DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell. 2008 Jun;13(6):529-41.

  5. Bourque G, Leong B, Vega VB, Chen X, Lee YL, Srinivasan KG, Chew JL, Ruan Y, Wei CL, Ng HH, Liu ET.. Evolution of the mammalian transcription factor binding repertoire via transposable elements. Genome Res. 2008 Aug 5. [Epub ahead of print]

  6. Barnett DH, Sheng S, Charn TH, Waheed A, Sly WS, Lin CY, Liu ET., Katzenellenbogen BS. Estrogen receptor regulation of carbonic anhydrase XII through a distal enhancer in breast cancer. Cancer Res. 2008 May 1;68(9):3505-15.